Myogen Inc Sample Contracts

MYOGEN, INC.
Stock Purchase Agreement • August 28th, 2003 • Myogen Inc • Colorado
AutoNDA by SimpleDocs
EXHIBIT 10.34 SECURITIES PURCHASE AGREEMENT dated as of September 24, 2004,
Securities Purchase Agreement • September 29th, 2004 • Myogen Inc • Pharmaceutical preparations • New York
MYOGEN, INC.
License Agreement • October 28th, 2003 • Myogen Inc • Pharmaceutical preparations • Colorado
JOINT FILING AGREEMENT
Joint Filing Agreement • October 8th, 2004 • Myogen Inc • Pharmaceutical preparations

Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13D to which this Agreement is attached as an Exhibit (the "Schedule 13D"), and any amendments thereto, will be filed with the Securities and Exchange Commission jointly on behalf of the undersigned. This Agreement may be executed in one or more counterparts.

RECITALS
Lease • March 1st, 2004 • Myogen Inc • Pharmaceutical preparations
MYOGEN, INC.
Preferred Stock Purchase Agreement • August 28th, 2003 • Myogen Inc • Colorado
MYOGEN, INC.
Myogen Inc • August 28th, 2003 • Delaware
RECITALS
Indemnity Agreement • March 1st, 2004 • Myogen Inc • Pharmaceutical preparations • Delaware
MYOGEN, INC., ISSuER AND [TRUSTEE], TRUSTEE INDENTURE
Myogen Inc • November 16th, 2005 • Pharmaceutical preparations • New York
MYOGEN, INC., ISSuER AND [TRUSTEE], TRUSTEE INDENTURE
Myogen Inc • June 3rd, 2005 • Pharmaceutical preparations • New York
WITNESSETH
License Agreement • October 28th, 2003 • Myogen Inc • Pharmaceutical preparations • Illinois
RECITALS
Investor Rights Agreement • August 28th, 2003 • Myogen Inc • Colorado
THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT
Stockholders Agreement • August 28th, 2003 • Myogen Inc • Colorado
WITNESSETH
Exclusive License Agreement • October 28th, 2003 • Myogen Inc • Pharmaceutical preparations • Illinois
MYOGEN, INC.
Myogen Inc • October 1st, 2003 • Pharmaceutical preparations • New York
AutoNDA by SimpleDocs
RECITALS
Patent and Technology License Agreement • March 1st, 2004 • Myogen Inc • Pharmaceutical preparations
INTRODUCTION
Development and Commercialization Agreement • October 28th, 2003 • Myogen Inc • Pharmaceutical preparations • Massachusetts
MYOGEN, INC.
Series D Preferred Stock Purchase Agreement • August 28th, 2003 • Myogen Inc • Colorado
PREAMBLE
License Agreement • May 9th, 2006 • Myogen Inc • Pharmaceutical preparations • New York
Repayment Period: 36 months Treasury Note Maturity: 36 months Loan Margin: 770 basis points
Venture Loan and Security Agreement • August 28th, 2003 • Myogen Inc • California
ExhibitA-2 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (For HDAC Inhibitor Compounds)
Development and Commercialization Agreement • August 9th, 2006 • Myogen Inc • Pharmaceutical preparations • Massachusetts

This License, Development and Commercialization Agreement (this “Agreement”) is made this day of , 200___ by and between Myogen, Inc. (“Myogen”), a Delaware corporation with principal offices at 7575 West 103rd Avenue, Westminster, Colorado 80021, and Novartis Institutes for BioMedical Research, Inc. (“NIBRI”), a Delaware corporation with principal offices at 400 Technology Square, Cambridge, Massachusetts 02139.

Myogen, Inc. 4,675,082 Shares of Common Stock, par value $0.001 per share Underwriting Agreement
Myogen Inc • September 16th, 2005 • Pharmaceutical preparations

As representatives of the several Underwriters named in Schedule A hereto, c/o Goldman, Sachs & Co., 85 Broad Street, New York, New York 10004

AMENDMENT TO COLLABORATION AND OPTION AGREEMENT
Collaboration and Option Agreement • May 26th, 2005 • Myogen Inc • Pharmaceutical preparations

This Amendment to Collaboration and Option Agreement (“Amendment”) is entered into as of May 23, 2005 (the “Amendment Date”) by and between Myogen, Inc. (“Myogen”), a Delaware corporation with principal offices at 7575 W. 103rd Avenue, Westminster, Colorado 80021, and Novartis Institutes for BioMedical Research, Inc. (“NIBRI”), a Delaware corporation with principal offices at 400 Technology Square, Cambridge, Massachusetts 02139.

Exhibit A-1 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
License, Development and Commercialization Agreement • August 9th, 2006 • Myogen Inc • Pharmaceutical preparations • Massachusetts

This License, Development and Commercialization Agreement (this “Agreement”) is made this day of , 200___ by and between Myogen, Inc. (“Myogen”), a Delaware corporation with principal offices at 7575 West 103rd Avenue, Westminster, Colorado 80021, and Novartis Institutes for BioMedical Research, Inc. (“NIBRI”), a Delaware corporation with principal offices at 400 Technology Square, Cambridge, Massachusetts 02139.

THIRD AMENDMENT TO LEASE
Lease • October 1st, 2004 • Myogen Inc • Pharmaceutical preparations

This Third Amendment to Lease Agreement (“Third Amendment”) is to be effective upon the closing of the Purchase and Sale Contract, Church Ranch Business Park, entered into by and between Scott Kaufman (“Landlord”) and LaSalle Bank, N.A., made and entered into effective as of July 30, 2004 (“Effective Date”) and is entered into by and between Landlord and Myogen, Inc. (“Tenant”). The Tenant and Landlord may be referred to herein as the “Parties” and either one of them may be referred to herein as a “Party”.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!